Tech Company Financing Transactions
Biodesy Funding Round
On 1/25/2016, Biodesy raised $10 million in Series B funding from 5AM Ventures, Pfizer Venture Investments and Roche Venture Fund.
Transaction Overview
Company Name
Announced On
1/25/2016
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series B
Investors
5AM Ventures (Lead Investor) (Andrew Schwab)
Pfizer Venture Investments (William Burkoth)
Proceeds Purpose
Proceeds from the financing will be used to expand and accelerate commercialization of the Biodesy Delta System, a new, real-time, high-throughput platform that enables researchers to measure conformational change in their own laboratories.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
170 Harbor Way 100
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Biodesy is developing technology to directly measure both changes in protein shape and function in real time.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ariel Notcovich
Chief Financial Officer
Gayle Kuokka
VP - Engineering
Lou Dietz
Browse more venture capital transactions:
Prev: 1/25/2016: Dorsata venture capital transaction
Next: 1/25/2016: Lucid VR venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs